Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1990 1
1993 1
1994 1
2002 1
2015 1
2022 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Evaluation of Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV/ΔNS2/Δ1313/I1314L and RSV/276 in RSV-Seronegative Children.
Cunningham CK, Karron RA, Muresan P, Kelly MS, McFarland EJ, Perlowski C, Libous J, Oliva J, Jean-Philippe P, Moye J, Schappell E, Barr E, Rexroad V, Johnston B, Chadwick EG, Cielo M, Paul M, Deville JG, Aziz M, Yang L, Luongo C, Collins PL, Buchholz UJ; International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) 2018 Study Team. Cunningham CK, et al. J Infect Dis. 2022 Dec 13;226(12):2069-2078. doi: 10.1093/infdis/jiac253. J Infect Dis. 2022. PMID: 35732186 Free PMC article. Clinical Trial.
Care of patients with ST-elevation myocardial infarction: an international analysis of quality indicators in the acute coronary syndrome STEMI Registry of the EURObservational Research Programme and ACVC and EAPCI Associations of the European Society of Cardiology in 11 462 patients.
Ludman P, Zeymer U, Danchin N, Kala P, Laroche C, Sadeghi M, Caporale R, Shaheen SM, Legutko J, Iakobishvili Z, Alhabib KF, Motovska Z, Studencan M, Mimoso J, Becker D, Alexopoulos D, Kereseselidze Z, Stojkovic S, Zelveian P, Goda A, Mirrakhimov E, Bajraktari G, Farhan HA, Šerpytis P, Raungaard B, Marandi T, Moore AM, Quinn M, Karjalainen PP, Tatu-Chitoiu G, Gale CP, Maggioni AP, Weidinger F; ACVC-EAPCI EORP ACS STEMI investigators group of the ESC. Ludman P, et al. Eur Heart J Acute Cardiovasc Care. 2023 Jan 27;12(1):22-37. doi: 10.1093/ehjacc/zuac143. Eur Heart J Acute Cardiovasc Care. 2023. PMID: 36346109
Moclobemide excretion in human breast milk.
Pons G, Schoerlin MP, Tam YK, Moran C, Pfefen JP, Francoual C, Pedarriosse AM, Chavinie J, Olive G. Pons G, et al. Br J Clin Pharmacol. 1990 Jan;29(1):27-31. doi: 10.1111/j.1365-2125.1990.tb03598.x. Br J Clin Pharmacol. 1990. PMID: 2297459 Free PMC article.
Moclobemide, and its major metabolite (Ro 12-8095) were measured in milk and plasma samples using h.p.l.c. The active metabolite (Ro 12-5637) could only be detected in plasma. 4. ...
Moclobemide, and its major metabolite (Ro 12-8095) were measured in milk and plasma samples using h.p.l.c. The active m …
Lack of pharmacokinetic interaction between the oral anti-influenza neuraminidase inhibitor prodrug oseltamivir and antacids.
Snell P, Oo C, Dorr A, Barrett J. Snell P, et al. Br J Clin Pharmacol. 2002 Oct;54(4):372-7. doi: 10.1046/j.1365-2125.2002.01678.x. Br J Clin Pharmacol. 2002. PMID: 12392584 Free PMC article. Clinical Trial.
Plasma and urine concentrations of oseltamivir and Ro 64-0802 were measured using a validated h.p.l.c./MS/MS assay. Pharmacokinetic parameters were calculated for oseltamivir and Ro 64-0802. ...
Plasma and urine concentrations of oseltamivir and Ro 64-0802 were measured using a validated h.p.l.c./MS/MS assay. Pha …
Rationale for Prospective Assays of Intrathecal Mixtures Including Morphine, Ropivacaine and Ziconotide: Prevention of Adverse Events and Feasibility in Clinical Practice.
Dupoiron D, Devys C, Bazin C, Folliard C, Lebrec N, Boré F, Dubois PY, Kieffer H. Dupoiron D, et al. Pain Physician. 2015 Jul-Aug;18(4):349-57. Pain Physician. 2015. PMID: 26218938 Free article.
SETTINGS: Assays were performed on all intrathecal admixtures produced by the ICO-Paul Papin compounding pharmacy between January 2013 and October 2014 using Ultra High Performance Liquid Chromatography (U.H.P.L.C.). ...
SETTINGS: Assays were performed on all intrathecal admixtures produced by the ICO-Paul Papin compounding pharmacy between January 201 …
Reversible enzymic protection of the alpha-amino group of amino acid derivatives using an aminopeptidase A.
Yoshpe-Besançon I, Auriol D, Paul F, Monsan P, Gripon JC, Ribadeau-Dumas B. Yoshpe-Besançon I, et al. Biotechnol Appl Biochem. 1993 Aug;18(1):93-102. Biotechnol Appl Biochem. 1993. PMID: 8397888
The following L-malyl derivatives were synthesized in thermodynamically controlled reactions with yields ranging from 4 to 47%: L-malyl-Tyr-OEt, -ALA-OMe, -Ser-OEt, -Lys-OEt, -Phe-OMe, -Met-NH2, -Glu-MH2, Arg-NH2, -Tye-NH2, -Val-NH2, -Ala-Phe and -Ala-Phe-NH2 (OEt and OMe are eth …
The following L-malyl derivatives were synthesized in thermodynamically controlled reactions with yields ranging from 4 to 47%: L-malyl-Tyr- …
Biotransformation of caffeine in human liver microsomes from foetuses, neonates, infants and adults.
Cazeneuve C, Pons G, Rey E, Treluyer JM, Cresteil T, Thiroux G, D'Athis P, Olive G. Cazeneuve C, et al. Br J Clin Pharmacol. 1994 May;37(5):405-12. doi: 10.1111/j.1365-2125.1994.tb05706.x. Br J Clin Pharmacol. 1994. PMID: 8054245 Free PMC article.
Caffeine and its metabolites, 1-3-7-trimethyluric acid, paraxanthine, theophylline and theobromine, were assayed by h.p.l.c. Methoxyresorufin-O-demethylase activity (MEROD) was determined and immunoquantifiable levels of CYP1A2 were measured. 2. ...
Caffeine and its metabolites, 1-3-7-trimethyluric acid, paraxanthine, theophylline and theobromine, were assayed by h.p.l.c …
Receptor binding of guinea pig and pig vasoactive intestinal peptides by rat lung.
Paul S, Volle DJ, Currie J. Paul S, et al. Biochem J. 1988 Sep 1;254(2):613-5. doi: 10.1042/bj2540613. Biochem J. 1988. PMID: 2845959 Free PMC article.
Degradation of gpVIP by rat lung membranes, assessed by radioimmunoassay and h.p.l.c., was 1.9-fold greater than that of pVIP. This difference in degradation of the two peptides was not large enough to account for the lower receptor-binding potency of gpVIP. …
Degradation of gpVIP by rat lung membranes, assessed by radioimmunoassay and h.p.l.c., was 1.9-fold greater than that o …